ClinicalTrials.Veeva

Menu

High Flow Nasal Cannula in Comparison With Nasal Continuous Positive Airway Pressure in the Management of Respiratory Distress Syndrome

S

Sidra Medicine

Status

Completed

Conditions

Respiratory Distress Syndrome

Treatments

Device: NCPAP
Device: HHHFNC

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

To compare the primary outcome, failure of extubation defined by the need for re-intubation and mechanical ventilation within 5 days of initial extubation and secondary outcomes, morbidities and mortality after using of heated humidity high flow nasal cannula (HHHFNC) and Nasal Continuous Positive Airway Pressure (NCPAP) in the immediate post-extubation period for preterm infants between 24 and 28 weeks gestation with respiratory distress syndrome.

Full description

Inclusion criteria were: 1) Preterm neonates with gestational age of 24 to 28 completed weeks. 2) In the case of twins, both neonates were included in the same treatment arm. 3) Success to wean with 24 hours to extubate. 4) Parental written informed consent for participation in the study obtained on admission into the hospital or prior to delivery.

Exclusion criteria were: 1) Evidence of severe birth asphyxia. 2) Known genetic or chromosomal disorders. 3) Infants delivered to mothers with ruptured membranes of more than three weeks duration. 4) Potentially life-threatening conditions unrelated to prematurity. 5) Participation in another clinical trial of any placebo, drug, biological, or device conducted under the provisions of a protocol.

Randomization A computer-generated block-randomization sequence with random block sizes was used. Infants who were part of multiple births underwent individual randomization. Clinicians opened consecutively numbered, sealed, brown envelopes immediately before extubation to determine the study-group assignment.

Enrollment

60 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Preterm neonates with gestational age of 24 to 28 completed weeks.
  2. In the case of twins, both neonates were included in the same treatment arm.
  3. Success to wean with 24 hours to extubate.
  4. Parental written informed consent for participation in the study obtained on admission into the hospital or prior to delivery.

Exclusion criteria

  1. Evidence of severe birth asphyxia.
  2. Known genetic or chromosomal disorders.
  3. Infants delivered to mothers with ruptured membranes of more than three weeks duration.
  4. Potentially life-threatening conditions unrelated to prematurity.
  5. Participation in another clinical trial of any placebo, drug, biological, or device conducted under the provisions of a protocol.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

60 participants in 2 patient groups

HHHFNC
Active Comparator group
Description:
Randomized to HHHFNC
Treatment:
Device: HHHFNC
NCPAP
Active Comparator group
Description:
Randomized to NCPAP
Treatment:
Device: NCPAP

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems